Tonix Pharmaceuticals (TNXP) Competitors $35.17 -2.13 (-5.71%) Closing price 07/2/2025 04:00 PM EasternExtended Trading$35.88 +0.71 (+2.02%) As of 07:14 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock TNXP vs. AKBA, RCUS, AVDL, PHVS, NRIX, SYRE, LENZ, MLYS, ZYME, and ARDXShould you be buying Tonix Pharmaceuticals stock or one of its competitors? The main competitors of Tonix Pharmaceuticals include Akebia Therapeutics (AKBA), Arcus Biosciences (RCUS), Avadel Pharmaceuticals (AVDL), Pharvaris (PHVS), Nurix Therapeutics (NRIX), Spyre Therapeutics (SYRE), LENZ Therapeutics (LENZ), Mineralys Therapeutics (MLYS), Zymeworks (ZYME), and Ardelyx (ARDX). These companies are all part of the "pharmaceutical products" industry. Tonix Pharmaceuticals vs. Its Competitors Akebia Therapeutics Arcus Biosciences Avadel Pharmaceuticals Pharvaris Nurix Therapeutics Spyre Therapeutics LENZ Therapeutics Mineralys Therapeutics Zymeworks Ardelyx Akebia Therapeutics (NASDAQ:AKBA) and Tonix Pharmaceuticals (NASDAQ:TNXP) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, media sentiment, valuation, earnings, dividends, institutional ownership, profitability and analyst recommendations. Do analysts rate AKBA or TNXP? Akebia Therapeutics presently has a consensus target price of $6.75, indicating a potential upside of 85.95%. Tonix Pharmaceuticals has a consensus target price of $585.00, indicating a potential upside of 1,563.35%. Given Tonix Pharmaceuticals' higher possible upside, analysts clearly believe Tonix Pharmaceuticals is more favorable than Akebia Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Akebia Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20Tonix Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more risk & volatility, AKBA or TNXP? Akebia Therapeutics has a beta of 0.88, indicating that its stock price is 12% less volatile than the S&P 500. Comparatively, Tonix Pharmaceuticals has a beta of 2.05, indicating that its stock price is 105% more volatile than the S&P 500. Which has higher earnings and valuation, AKBA or TNXP? Akebia Therapeutics has higher revenue and earnings than Tonix Pharmaceuticals. Akebia Therapeutics is trading at a lower price-to-earnings ratio than Tonix Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAkebia Therapeutics$160.18M5.95-$69.41M-$0.21-17.29Tonix Pharmaceuticals$10.09M25.65-$130.04M-$1.96 thousand-0.02 Is AKBA or TNXP more profitable? Akebia Therapeutics has a net margin of -24.51% compared to Tonix Pharmaceuticals' net margin of -1,313.87%. Akebia Therapeutics' return on equity of 0.00% beat Tonix Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Akebia Therapeutics-24.51% N/A -18.92% Tonix Pharmaceuticals -1,313.87%-120.96%-101.28% Do insiders and institutionals hold more shares of AKBA or TNXP? 33.9% of Akebia Therapeutics shares are held by institutional investors. Comparatively, 82.3% of Tonix Pharmaceuticals shares are held by institutional investors. 3.0% of Akebia Therapeutics shares are held by company insiders. Comparatively, 0.0% of Tonix Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Does the media prefer AKBA or TNXP? In the previous week, Tonix Pharmaceuticals had 5 more articles in the media than Akebia Therapeutics. MarketBeat recorded 13 mentions for Tonix Pharmaceuticals and 8 mentions for Akebia Therapeutics. Akebia Therapeutics' average media sentiment score of 0.72 beat Tonix Pharmaceuticals' score of 0.17 indicating that Akebia Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Akebia Therapeutics 4 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tonix Pharmaceuticals 0 Very Positive mention(s) 2 Positive mention(s) 11 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryAkebia Therapeutics beats Tonix Pharmaceuticals on 11 of the 17 factors compared between the two stocks. Get Tonix Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for TNXP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TNXP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TNXP vs. The Competition Export to ExcelMetricTonix PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$274.42M$2.42B$5.54B$8.87BDividend YieldN/A1.77%5.39%4.10%P/E Ratio-0.028.8326.2319.90Price / Sales25.65663.86413.23113.66Price / CashN/A151.5836.1356.90Price / Book1.114.548.045.38Net Income-$130.04M$31.16M$3.15B$248.50M7 Day Performance-1.04%-0.40%1.44%2.04%1 Month Performance-13.05%6.76%3.62%4.84%1 Year Performance-60.66%1.17%34.68%20.23% Tonix Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TNXPTonix Pharmaceuticals2.7819 of 5 stars$35.17-5.7%$585.00+1,563.3%-52.3%$274.42M$10.09M-0.0250AKBAAkebia Therapeutics4.2759 of 5 stars$3.60-2.3%$6.75+87.8%+278.1%$946.82M$160.18M-17.17430Positive NewsInsider TradeRCUSArcus Biosciences2.8474 of 5 stars$8.67+0.5%$24.13+178.4%-41.4%$916.44M$141M-2.07500AVDLAvadel Pharmaceuticals2.5607 of 5 stars$9.47+3.1%$18.17+91.9%-36.6%$915.74M$169.12M-35.0670PHVSPharvaris1.481 of 5 stars$17.29-3.9%$36.20+109.4%+5.8%$903.83MN/A-5.7430Gap UpNRIXNurix Therapeutics1.3748 of 5 stars$11.86+3.2%$30.18+154.5%-34.3%$903.78M$56.42M-4.23300News CoverageUpcoming EarningsAnalyst RevisionSYRESpyre Therapeutics1.9635 of 5 stars$14.73-1.9%$53.40+262.6%-34.8%$887.62M$890K-3.9173LENZLENZ Therapeutics1.3529 of 5 stars$30.60+2.2%$46.60+52.3%+76.5%$871.10MN/A-17.48110MLYSMineralys Therapeutics2.3371 of 5 stars$13.31-1.3%$32.25+142.3%+18.3%$867.68MN/A-3.5728ZYMEZymeworks1.9669 of 5 stars$12.44-0.4%$21.00+68.9%+53.5%$866.79M$93.38M-8.31460ARDXArdelyx4.3664 of 5 stars$3.59+0.7%$10.89+203.7%-20.6%$857.75M$333.61M-16.3090 Related Companies and Tools Related Companies Akebia Therapeutics Alternatives Arcus Biosciences Alternatives Avadel Pharmaceuticals Alternatives Pharvaris Alternatives Nurix Therapeutics Alternatives Spyre Therapeutics Alternatives LENZ Therapeutics Alternatives Mineralys Therapeutics Alternatives Zymeworks Alternatives Ardelyx Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TNXP) was last updated on 7/3/2025 by MarketBeat.com Staff From Our PartnersTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredA grave, grave error.President Donald Trump made headlines last month with a staggering claim. He stated that since taking offic...Porter & Company | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe $100 Trillion AI Story No One Is Telling YouJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tonix Pharmaceuticals Holding Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tonix Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
